Abstract
In the present investigation, a series of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2- c]pyrazole-2-carboxamide analogs were synthesized based on the structure of known antitubercular drug thiacetazone and were evaluated for antitubercular activity by two fold serial dilution technique. A computational study was carried out for prediction of pharmacokinetic properties and none of the compounds violated Lipinski “Rule of Five”. The structures of the synthesized compounds were confirmed on the basis of their spectral data and elemental analysis. All the newly synthesized compounds showed low to good activity inhibitory activities against Mycobacterium tuberculosis H37Rv (MTB) and isoniazid resistant M. tuberculosis (INHR-MTB). 3-(4-fluoromethyl)-N-(2-chlorophenyl)-6,7-dimethoxy-3a,4- dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide (4c) was found to be the most promising compound active against M. tuberculosis H37Rv and isoniazid resistant M. tuberculosis (INHR-MTB) with minimum inhibitory concentration 0.83 and 3.35 μM respectively.
Keywords: Pyrazolines, claisen schmidt condensation, antitubercular agents, molecular properties prediction, lipophilicity; lipinski “rule of five”
Anti-Infective Agents
Title:Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents
Volume: 10 Issue: 2
Author(s): Mohamed Jawed Ahsan, Jeyabalan Govinda Samy, Habibullah Khalilullah, Choudhary R. Kirit and Savita Soni
Affiliation:
Keywords: Pyrazolines, claisen schmidt condensation, antitubercular agents, molecular properties prediction, lipophilicity; lipinski “rule of five”
Abstract: In the present investigation, a series of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2- c]pyrazole-2-carboxamide analogs were synthesized based on the structure of known antitubercular drug thiacetazone and were evaluated for antitubercular activity by two fold serial dilution technique. A computational study was carried out for prediction of pharmacokinetic properties and none of the compounds violated Lipinski “Rule of Five”. The structures of the synthesized compounds were confirmed on the basis of their spectral data and elemental analysis. All the newly synthesized compounds showed low to good activity inhibitory activities against Mycobacterium tuberculosis H37Rv (MTB) and isoniazid resistant M. tuberculosis (INHR-MTB). 3-(4-fluoromethyl)-N-(2-chlorophenyl)-6,7-dimethoxy-3a,4- dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide (4c) was found to be the most promising compound active against M. tuberculosis H37Rv and isoniazid resistant M. tuberculosis (INHR-MTB) with minimum inhibitory concentration 0.83 and 3.35 μM respectively.
Export Options
About this article
Cite this article as:
Jawed Ahsan Mohamed, Govinda Samy Jeyabalan, Khalilullah Habibullah, R. Kirit Choudhary and Soni Savita, Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020117
DOI https://dx.doi.org/10.2174/2211362611208020117 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design Adverse Drug Reactions: Trends in a Tertiary Care Hospital
Current Drug Safety The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Eidtorial from Editor-in-Chief : [ Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012 ]
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety NO-NSAIDs: From Inflammatory Mediators to Clinical Readouts
Inflammation & Allergy - Drug Targets (Discontinued) Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews Patent Selections
Recent Patents on Food, Nutrition & Agriculture Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Optimal Oxygen Therapy in the Critically Ill Patient with Respiratory Failure
Current Respiratory Medicine Reviews